Argent BioPharma マネジメント

マネジメント基準チェック /34

Argent BioPharma'sの CEO はRoby Zomerで、 Feb2016年に任命され、の在任期間は 8.33年です。の年間総報酬はA$ 354.02Kで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.075%を直接所有しており、その価値は€ 6.51K 。経営陣と取締役会の平均在任期間はそれぞれ1.9年と3.5年です。

主要情報

Roby Zomer

最高経営責任者

AU$417.1k

報酬総額

CEO給与比率	92.8%
CEO在任期間	8.7yrs
CEOの所有権	19.2%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Argent BioPharma の収益と比較して、Roby Zomer の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$417k	AU$387k	-AU$18m
Mar 31 2024	n/a	n/a	-AU$17m
Dec 31 2023	n/a	n/a	-AU$17m
Sep 30 2023	n/a	n/a	-AU$19m
Jun 30 2023	AU$354k	AU$354k	-AU$21m
Mar 31 2023	n/a	n/a	-AU$22m
Dec 31 2022	n/a	n/a	-AU$23m
Sep 30 2022	n/a	n/a	-AU$22m
Jun 30 2022	AU$629k	AU$422k	-AU$20m
Mar 31 2022	n/a	n/a	-AU$19m
Dec 31 2021	n/a	n/a	-AU$18m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	AU$481k	AU$281k	-AU$16m
Dec 31 2020	n/a	n/a	-AU$13m
Sep 30 2020	n/a	n/a	-AU$16m
Jun 30 2020	AU$440k	AU$290k	-AU$19m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$14m
Jun 30 2019	AU$495k	AU$330k	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$498k	AU$334k	-AU$8m

報酬と市場: Robyの総報酬 ($USD 236.25K ) は、 German市場 ($USD 434.45K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Robyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Roby Zomer (44 yo)

8.7yrs

在職期間

AU$417,064

報酬

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Roby Zomer	Co-Founder	8.7yrs	AU$417.06k	19.2% € 1.7m
Igor Bluvstein	Chief Financial Officer	less than a year	データなし	データなし
Yifat Steuer	Deputy CEO & COO	2yrs	データなし	37.79% € 3.4m
Shachar Shimony	Group General Counsel	no data	データなし	データなし
Masa Oblak	People Manager	no data	データなし	データなし
Amir Polak	Chief Pharmaceutical Development Officer	no data	データなし	データなし
Sabina Suljakovic	Chief Quality and Commercial Officer	4.1yrs	データなし	データなし
Nadya Lisovoder	Chief Medical Officer	no data	データなし	データなし
Sasha Friedman	Deputy CEO	no data	データなし	データなし
Yair Tal	Chief Information Security Officer	no data	データなし	データなし
Rowan Harland	Company Secretary	1.6yrs	データなし	データなし
Ana Oblak	Group Financial Controller	no data	データなし	データなし

2.0yrs

平均在職期間

経験豊富な経営陣: H5O0の経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Roby Zomer	Co-Founder	8.7yrs	AU$417.06k	19.2% € 1.7m
Ross Grant Walker	Chairman of Strategic Advisory Board	no data	AU$32.00k	0.010% € 912.3
Uri Kramer	Member of Strategic Advisory Board	8.3yrs	データなし	データなし
Layton Mills	Independent Non-Executive Director	1.3yrs	AU$61.92k	データなし
Wendyl D'Souza	Member of Medical Advisory Board	6.3yrs	データなし	データなし
Daniel Robinson	Non-Executive Director	less than a year	AU$41.92k	データなし
Shlomo Sadoun	Member of Advisory Board	less than a year	データなし	データなし

3.8yrs

平均在職期間

経験豊富なボード: H5O0の取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Argent BioPharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Co-Founder recently bought €1.0m worth of stock

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Less than half of directors are independent

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

Less than half of directors are independent

Recent updates

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Co-Founder recently bought €1.0m worth of stock

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Less than half of directors are independent

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

Less than half of directors are independent

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System

Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences

マネジメント基準チェック /34